Adoption of rimegepant in Denmark: a register-based study on uptake, prescribing patterns and initiator characteristics [PDF]
The Journal of Headache and PainBackground Rimegepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist, is the first drug within its class approved for both acute and preventive treatment of migraine. This study examines its uptake in Denmark.
Lanfranco Pellesi +4 more
doaj +7 more sources
Antagonism of CGRP Signaling by Rimegepant at Two Receptors [PDF]
Frontiers in Pharmacology, 2020 The “gepants” are a class of calcitonin gene-related peptide (CGRP) receptor antagonist molecules that have been developed for the prevention and treatment of migraine.
Andrew Siow +2 more
exaly +5 more sources
Short-term prevention of perimenstrual migraine with rimegepant [PDF]
The Journal of Headache and PainBackground Menstrually-related migraine (MRM) affects approximately 31–52% of women with migraine and are characterized by increased frequency, severity, and reduced response to conventional therapy during the perimenstrual window. Traditional short-term
Florian Frank +4 more
doaj +3 more sources
Evaluating rimegepant for the treatment of migraine [PDF]
Expert Opinion on Pharmacotherapy, 2021 IntroductionCalcitonin gene-related peptide (CGRP) is a vasodilatory neuropeptide involved in the pathophysiology of migraine, a highly disabling neurovascular disorder characterized by severe headache attacks. Rimegepant is a small-molecule CGRP receptor antagonist approved by the FDA for acute treatment of migraine and currently under investigation ...
Tessa de Vries +2 more
exaly +3 more sources
A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention [PDF]
The Journal of Headache and PainBackground Rimegepant is a small-molecule calcitonin gene-related peptide receptor antagonist approved in adults for acute treatment of migraine (with or without aura) and preventive treatment of episodic migraine (EM).
Jeremias Antinew +7 more
doaj +2 more sources
Long-term safety and effectiveness of rimegepant for the preventive treatment of migraine in Japan: an open-label extension of a phase 3 study [PDF]
The Journal of Headache and PainBackground The aim of the current analyses of a phase 3 randomized controlled trial conducted in Japan was to assess the long-term safety and effectiveness of rimegepant 75 mg, taken for up to 52 weeks, for the preventive treatment of migraine.
Yasuhiko Matsumori +10 more
doaj +2 more sources
Frontiers in Pharmacology, 2020 BackgroundAs one of the novel therapeutic drugs that targets Calcitonin gene-related peptide (CGRP), 75 mg rimegepant has been used for the acute management of migraine, which is one of the most common neurological diseases worldwide.
Zhouqing Chen, Zhong Wang
exaly +3 more sources
Exposure Matching Using Population Pharmacokinetic Modeling and Simulation to Support Rimegepant Dose Selection for Pediatric Patients With Migraine [PDF]
Clinical and Translational ScienceRimegepant is a small molecule calcitonin gene‐related peptide receptor antagonist approved as a 75 mg orally disintegrating tablet for the acute treatment of migraine and the prevention of episodic migraine in adults.
Craig M. Comisar +6 more
doaj +2 more sources
Testing rimegepant for migraine—time to revise the trial design? [PDF]
Lancet, The, 2020 We read with interest the results of the phase 3 trial by Robert Croop and colleagues1 on the use of rimegepant for treatment of acute migraine. We feel that this study, like other similarly designed trials, has major problems in its methods, which suggests caution should be taken when examining the results.
Sara Gasparini +2 more
exaly +4 more sources
Effectiveness of rimegepant in vestibular migraine: a prospective self-controlled cohort study [PDF]
The Journal of Headache and PainBackground Vestibular migraine (VM) is the second most common cause of episodic vertigo worldwide, yet effective therapeutic options remain limited. This study aimed to assess the clinical effectiveness of rimegepant in patients with VM.
Jinyan Shao +13 more
doaj +2 more sources